Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00559273 · BASELINE

Baseline characteristics

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis · Source last updated 2016-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      150
    2. group Id
      BG001
      value
      155
    3. group Id
      BG002
      value
      305
    units
    Participants
groups
  1. description
    Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
    id
    BG000
    title
    Mircera
  2. description
    Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
    id
    BG001
    title
    Darbepoetin Alfa
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          14.37
          value
          65.2
        2. group Id
          BG001
          spread
          13.40
          value
          67.4
        3. group Id
          BG002
          spread
          13.91
          value
          66.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          85
        2. group Id
          BG001
          value
          87
        3. group Id
          BG002
          value
          172
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          65
        2. group Id
          BG001
          value
          68
        3. group Id
          BG002
          value
          133
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Safety population included all randomized participants who received at least 1 dose of study medication and attended safety follow-up, whether they withdrew prematurely or not. Participants were assigned to the treatment group as treated. One participant randomized to Mircera, received darbepoetin alfa and included in darbepoetin alfa arm.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      150
    2. group Id
      BG001
      value
      155
    3. group Id
      BG002
      value
      305
    units
    Participants
groups
  1. description
    Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
    id
    BG000
    title
    Mircera
  2. description
    Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
    id
    BG001
    title
    Darbepoetin Alfa
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          14.37
          value
          65.2
        2. group Id
          BG001
          spread
          13.40
          value
          67.4
        3. group Id
          BG002
          spread
          13.91
          value
          66.3
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          85
        2. group Id
          BG001
          value
          87
        3. group Id
          BG002
          value
          172
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          65
        2. group Id
          BG001
          value
          68
        3. group Id
          BG002
          value
          133
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Safety population included all randomized participants who received at least 1 dose of study medication and attended safety follow-up, whether they withdrew prematurely or not. Participants were assigned to the treatment group as treated. One participant randomized to Mircera, received darbepoetin alfa and included in darbepoetin alfa arm.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice